ISM 6331
Alternative Names: ISM-6331; TEAD transcription factors targeting therapeutic - InSilico MedicineLatest Information Update: 06 Aug 2026
At a glance
- Originator InSilico Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Yes - Mesothelioma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Mesothelioma; Solid tumours
Most Recent Events
- 29 Jul 2026 ISM 6331 receives Fast track status from the US FDA for Mesothelioma (Late stage disease, Inoperable/Unresectable, Second-line therapy or greater)
- 30 Dec 2024 Phase-I clinical trials in Mesothelioma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06566079)
- 30 Dec 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06566079)